Intellia Therapeutics Inc NTLA:NASDAQ

Last Price$106.92NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/01/21

Today's Change-8.09(7.03%)
Bid (Size)$100.76 (1)
Ask (Size)$114.09 (1)
Day Low / High$106.90 - 117.70
Volume958.9 K
  • Latest Stories
  • Commentary and Analysis
Intellia Therapeutics Expands Phase 1 Study of NTLA-2001 to Patients With Transthyretin Amyloidosis With Cardiomyopathy
9:32AM ET 11/22/2021 MT Newswires

Intellia Therapeutics (NTLA) said Monday that it's expanding its phase 1 study of NTLA-2001 to include adults with transthyretin amyloidosis with...

--HC Wainwright Adjusts Intellia Therapeutics' Price Target to $182 from $171, Keeps Buy Rating
11:33AM ET 11/05/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Oppenheimer Adjusts Intellia Therapeutics PT to $145 From $160, Maintains Perform Rating
10:46AM ET 11/05/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Wedbush Adjusts Price Target for Intellia Therapeutics to $137 From $130, Maintains Neutral Rating
2:59PM ET 11/04/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Intellia Therapeutics Widens Loss in Q3, Revenue Drops
7:56AM ET 11/04/2021 MT Newswires

Intellia Therapeutics (NTLA) reported Thursday a Q3 net loss of $0.97, compared with a loss of $0.47 a year ago. Analysts polled by Capital IQ expected a...

Intellia Therapeutics Obtains US FDA Orphan Drug Designation for Rare Disease Gene Editing Therapy
9:05AM ET 10/21/2021 MT Newswires

Intellia Therapeutics (NTLA) said Thursday the US Food and Drug Administration has granted orphan drug designation to its investigational gene editing...

Intellia Therapeutics Says Preclinical Data Shows Advancements in Broad Genome Editing Capabilities
12:29PM ET 10/20/2021 MT Newswires

Intellia Therapeutics (NTLA) said Wednesday that preclinical data showed new capabilities of its genome editing platform, which the company plans to use...

Insider Sell: Intellia Therapeutics
4:34PM ET 10/13/2021 MT Newswires

John F Crowley, Director, on October 11, 2021, sold 2,500 shares in Intellia Therapeutics (NTLA) for $298,875. Following the Form 4 filing with the SEC,...

Intellia Therapeutics, SparingVision Sign Deal to Develop Ocular Therapies
7:47AM ET 10/13/2021 MT Newswires

Intellia Therapeutics (NTLA) and SparingVision said they have signed a deal to develop medicines to treat ocular diseases. SparingVision will be given...

Insider Sell: Intellia Therapeutics
9:27AM ET 10/08/2021 MT Newswires

John F Crowley, Director, on October 05, 2021, sold 10,000 shares in Intellia Therapeutics (NTLA) for $1,305,391. Following the Form 4 filing with the SEC,...